Literature DB >> 7688827

Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

A Pinter1, W J Honnen, S A Tilley.   

Abstract

Two neutralizing human monoclonal antibodies (HuMAbs) directed against epitopes located near the tip of the V3 loop of human immunodeficiency virus type 1 env protein recognized solubilized gPr160, but not gp120, in radioimmunoprecipitation assays. Efficient immunoprecipitation of solubilized gp120 by these antibodies did occur in the presence of HuMAb 1125H, directed against a conformational epitope overlapping the CD4-binding site, or its F(ab')2 fragment. In contrast to the inability of the anti-V3 antibodies to immunoprecipitate solubilized gp120, these HuMAbs did bind to gp120 in intact virions; this level of binding increased severalfold in the presence of the F(ab')2 fragment of 1125H. These results demonstrate that neutralization epitopes in the V3 loop are sequestered in soluble gp120 but partly exposed in gPr160 and in virion-associated gp120 and that binding of antibodies to the discontinuous CD4-binding site leads to conformational changes that result in the exposure of V3 epitopes in soluble gp120 and their enhanced accessibility in gPr160 and in virion-associated gp120. Enhanced binding of suboptimal concentrations of 1125H to soluble gp120 was also induced by the presence of an anti-V3 HuMAb, indicating the occurrence of reciprocal allosteric interactions between the V3 loop and the CD4-binding site. It is likely that these effects contribute to the synergistic neutralization of human immunodeficiency virus type 1 previously reported for antibodies directed against these two regions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688827      PMCID: PMC237978     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation.

Authors:  J P Moore; P J Klasse
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

2.  Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Authors:  A Buchbinder; S Karwowska; M K Gorny; S T Burda; S Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

3.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

4.  Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells.

Authors:  B M Travis; T I Dykers; D Hewgill; J Ledbetter; T T Tsu; S L Hu; J B Lewis
Journal:  Virology       Date:  1992-01       Impact factor: 3.616

5.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.

Authors:  K A Page; S M Stearns; D R Littman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Improved antigenicity of the HIV env protein by cleavage site removal.

Authors:  M P Kieny; R Lathe; Y Rivière; K Dott; D Schmitt; M Girard; L Montagnier; J Lecocq
Journal:  Protein Eng       Date:  1988-09

7.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.

Authors:  L A Ivanoff; D J Looney; C McDanal; J F Morris; F Wong-Staal; A J Langlois; S R Petteway; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1991-07       Impact factor: 2.205

10.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.

Authors:  S A Tilley; W J Honnen; M E Racho; T C Chou; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

View more
  18 in total

1.  Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.

Authors:  H A Mbah; S Burda; M K Gorny; C Williams; K Revesz; S Zolla-Pazner; P N Nyambi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

5.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

6.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Azasugar-containing phosphorothioate oligonucleotide (AZPSON) DBM-2198 inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking HIV-1 gp120 without affecting the V3 region.

Authors:  Jinjoo Lee; Se Eun Byeon; Ju Yeol Jung; Myeong-Ho Kang; Yu-Jin Park; Kyeong-Eun Jung; Yong-Soo Bae
Journal:  Mol Cells       Date:  2015-01-27       Impact factor: 5.034

8.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.

Authors:  B T Korber; K MacInnes; R F Smith; G Myers
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.